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given as radical or adjuvant treatment for PC in 4 and 5 
patients respectively and as neoadjuvant therapy for rectal 
cancer in 1 case. The median dose of prior RT was 70 Gy 
(range 45-76) and the median time between the first and the 
second RT course was 117 months (range 95-219). The total 
dose of retreatment was 50 Gy in 5 patients and 60 Gy in 2 (2 
Gy daily fraction). Patients immobilized with Combifix device 
underwent planning computed tomography (CT) with 3-mm 
slice thickness; they were instructed to receive RT every day 
with an empty rectum and a full bladder. Clinical target 
volume (CTV) was the prostate in 5 and the PET positive 
nodule in 2 patients. Organs at risk (OAR) were: rectum, 
bladder, penile bulb and femoral heads. Planning target 
volume (PTV) was obtained by adding 3-5 mm to the 
corresponding CTV. The parameters used in HT planning 
system were: field width 1 or 2.5 cm, pitch 0.287 and 
modulation factor ranging from 2 to 3. Median duration of 
treatments was 180.7 seconds (range 145-347.8). 
Results: Median follow up was 7 months (range 3-38). All 
patients completed the reirradiation course. PTV median size 
was 66.65 cc (range 7.91 – 114.26). The cumulative mean 
dose (D mean) to the rectum ranged from 37.87 to 73.83 Gy 
and the cumulative rectal maximum dose (D max) ranged 
from 112.66 to 119.85 Gy. The cumulative D mean to the 
bladder ranged between 19.84 and 83.79 Gy; cumulative D 
max ranged from 93.99 to 126.3 Gy. When total dose was 50 
Gy, the OAR dose volume constraints were: V10< 40% and 
V25<10% for rectum; V10<20%, V25<10% and V44<2% for 
bladder. When total dose was 60 Gy the constraints were: 
V10<30% and V30<1% for rectum and V10<15%, V30<10% and 
V50<5% for bladder. Acute grade 2 genitourinary toxicity was 
observed in 3 patients and grade 2 gastrointestinal toxicity in 
1 patient. Three months after retreatment all patients had 
early PSA decrease; only 2 patients experienced biochemical 
relapse due to pelvic nodal recurrence. One patient died for 
bladder cancer.  
Conclusions: PC patients benefit from salvage reirradiation 
with HT. The treatment was feasible and well tolerated, with 
low rates of acute toxicity. Longer follow up is required to 
confirm retreatment safety and evaluate late toxicity. 
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Purpose/Objective: Even if many advances have been done 
in cancer care, clinical choices are based on evidence-based 
guidelines, resulted from large randomized trials often, and 
applicable only to population subset. Need of 'tailored 
treatment' can require specialized Decision Support System 
(DSS). Therefore, creation of large, and heterogeneous 
databases, could implement and validate DSS based on 
predictive models. In order to share the same meaning 
between people involved in the project, an ontology need to 
be created and shared. Our aim is to build a prostate cancer 
ontology able to represent a list of the main concepts 
involved in this semantic domain and how those concepts are 
related, by a graph. 
Materials and Methods: We built ontology starting from a 
well-defined data collection model, able to collect, 
standardize and organize concepts related with prostate 
cancer patients. These features were organized according 
three different levels. The first, Registry level, includes all 
general epidemiological information (age, gender, e.g.). The 
second, Procedure tier, includes information about treatment 
and toxicities, and outcome evaluation. The last, Research 
level, includes clinical, imaging and Quality of Life 
information for advanced research projects. Relationships 
between concepts have been added as last step. The so built 
ontology describes each of these concepts with a unique 
reference, preferably mapped to a published coding system 
(e.g. NCI Thesaurus, CTCAE).  
Results: Building an ontology is a good strategy to 
standardize data and procedure and create a consistent 
dataset. We selected more than 200 variables related with 
prostate cancer. The three data storing tiers were used to 
classify all the information to easily develop queries 
depending on the analysis different (epidemiological, 
toxicity, outcomes e.g.). Many concepts can be shared with 
ontologies related other cancer sites (general idea of 
toxicities, TNM, etc.) while others are prostate specific (PSA, 
etc.). We decided to adopt a trade-off between the formal 
explication of the ontology and the effective usability of it: 
even if a formal ontology is a powerful tool to allow 
automatic inference and represent in a not-ambiguous way a 
semantic, it is hard to be handled and properly validated.  
Conclusions: Sharing and combining multiple dataset, 
through structural collaboration between different groups, 
are the basis to generate large databases. Computer Science 
allows us to share concepts in a not ambiguous way in order 
to do that, by using ontologies and related languages. 
Through an ontology creation we obtained a standardized and 
organized dataset, easy to be shared and understood, not 
ambiguous, mapped on most common international standards 
and suitable to create predictive models which complement 
existing consensus or guidelines, moving from prescription by 
consensus to prescription by numbers.  
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Purpose/Objective: The aim of this study is to evaluate the 
changes in bladder doses during the volumetric modulated 
arc therapy (VMAT) treatment of prostate cancer patients 
using weekly cone beam computed tomography (CBCT) data. 
Materials and Methods: Ten consecutive patients with 
prostate cancer treated by radical RT were considered. For 
each patient, pre-treatment CBCT performed on a weekly 
basis were analyzed by using two different methods of target 
localization (intraprostatic fiducials and bony anatomy). To 
evaluate the changes in bladder doses; organs of interest 
were contoured on each weekly treatment CBCT data set and 
the images, along with the contours, were registered to the 
original planning CT. The replanning was made on planning 
CT using contours transfered from CBCT for two different 
